Polypill plus aspirin prevents primary CVD events in people at medium risk (TIPS-3)

Dp2

This multicentre, 2-by-2-by-2 factorial study randomised 5713 participants with medium cardiovascular disease (CVD) risk to receive a polypill (containing a statin and three blood pressure medications) or placebo daily, aspirin 75 mg daily or placebo and vitamin D or placebo monthly. The study took place between 2012 and 2017 and participants were followed up for […]

Polypill, including aspirin, is effective in reducing cardiovascular events

Dp2

The PolyIran study a pragmatic, cluster-randomised trial explored the utility of a fixed-dose polypill strategy for reducing cardiovascular disease (CVD). The polypill contained aspirin 81 mg, atorvastatin 20 mg, hydrochlorothiazide 12.5 mg and enalapril 5 mg. If participants developed a cough, they were changed to polypill two with valsartan 40mg replacing enalapril 5 mg. The […]

Low-dose aspirin reduces CRC risk by 11% in Taiwan study

Dp5

Low-dose aspirin reduces CRC risk by 11% in Taiwan study In Taiwan, low-dose aspirin is a prescription only drug used for cardiovascular disease prevention. This makes it easier to study who is taking and not taking the drug along with concordance rates. In this nested case-control study 4, 710 504 eligible individuals were identified from […]

Coronary artery calcium score marker for net benefit of aspirin

Dp2

2020 November A cohort study of participants from the Dallas Heart Study who were free from atherosclerotic cardiovascular disease and not taking aspirin at baseline were investigated to see the impact of increasing coronary artery calcium (CAC) on both bleeding and atherosclerotic cardiovascular disease (ASCVD) events. Having a higher CAC is a risk factor for […]

Research pioneers celebrated in Senior Science Award ceremony

Dp3

The international trialists Professors Lars Wallentin, Jan van Gijn, Bo Norrving and Tom Meade were recognised for their work on low-dose aspirin, with the presentation of the International Aspirin Foundation Senior Science Award. The Award, supported by Bayer AG, was presented at a virtual ceremony, during which the recipients gave both historic and up to […]

Aspirin contributes to improved CVD outcomes for people with type 2 diabetes

Dp3

Aspirin as part of a cardiovascular (CVD) prevention strategy has contributed towards a reduction in the risk of having a myocardial infarction (MI) in people with type 2 diabetes over the last 15 years. This Danish study, presented as a late breaker at the European Society of Cardiologists (ESC), is the first to examine the […]

Dr Andrew Chan receives prestigious National Cancer Institute Outstanding Investigator Award

Chan

The National Cancer Institute (NCI) has named International Aspirin Foundation’s Scientific Advisory Board member Andrew Chan MD MPH one of the 2020 recipients of its prestigious Outstanding Investigator Award (OIA). The NCI OIA is one of the most highly regarded research awards available to cancer investigators in the USA. The highly competitive award supports accomplished […]

Evidence that less is more – aspirin alone as an antiplatelet strategy to prevent clotting after a heart valve intervention

Dp2

Results from the POPular TAVI trial, presented as a Hot Line session at this year’s European Society of Cardiologists (ESC) Congress, have shown aspirin monotherapy to be superior to dual therapy with clopidogrel as an anti-platelet strategy, in people not on oral anticoagulants, following transcatheter aortic valve implantation (TAVI) for aortic stenosis. In this study, […]

NICE provide a patient decision aid for aspirin and Lynch syndrome

Dp5

In order to support the implementation of their colorectal cancer (CRC) guidelines, the National Institute for Health and Care Excellence (NICE), have published a patient decision aid to help clinicians enable people with Lynch syndrome to make fully informed choices about whether to take regular aspirin in order reduce their chance of getting bowel cancer. […]